Aix-en-Provence, may 22, 2017 – 8: 00am – SuperSonic Imagine (Euronext : SSI, FR0010526814, eligible PEA-PME), a company specialized in medical imaging by ultrasound (ultrasound), reaffirms and clarifies its strategic objectives.
Download the free guide
Boost your gains
SuperSonic Imagine has launched a capital increase of approximately € 10 million with maintenance of the preferential subscription right may 17, 2017. The proceeds of this capital increase will be intended to provide the Company additional resources needed to finance the i/ of its routine business, to the tune of about 60% of the funds raised, ii/ with the launch of its new, modular platform ultrasound, approximately 20% of the funds raised, and iii/ commercial development, marketing expenses, clinical studies and medico-economic, to the tune of approximately 20% of the funds raised.
The Company said that the funds allocated to the funding of the phase of industrialisation of its new platform should allow for a commercial launch in the second quarter 2018 in Europe and the United States, as well as in 2020 in China.
SuperSonic Imagine has operated in early 2016 strategic refocus around the clinical indications for high-potential, senology and hepatology, as well as on its three priority markets are China, the United States and France, on which SuperSonic Imagine operates in direct. This strategy has set out the guidelines and operational objectives clear medium and long term : complete a minimum of 40% of the turnover in clinical specialties, and to achieve a gross margin above 50% in the medium term, and reach the break-even point in terms of EBITDA on the year 2019, which will involve for the company an average annual growth double-digit, year 2017 included.
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in the area of medical imaging. The company designs, develops and markets a platform ultrasonographic revolutionary Aixplorer®, which operates a technology UltraFast to a frame rate about 200 times faster than scanners of conventional design. In addition to the exceptional quality of the images thus obtained, this unique technology has given birth to several innovations that have changed the paradigm in ultrasound imaging : Elastography ShearWave (SWE), the technology of Doppler UltraFast and, more recently, Angio PL.U.S, PLanewave UltraSensitive Imaging. The Elastography ShearWave allows physicians to visualize and analyze in real time the hardness of the tissue, thanks to a procedure reliable, reproducible, and noninvasive. An important parameter for the diagnosis of lesions potentially malignant or other diseased tissues. To date, more than 300 publications have demonstrated the value of SWE for the support of patients in a wide range of diseases. The Doppler Ultrafast combines the imaging of flow by color and pulsed Doppler in a single simple test, providing physicians with the results of the two operations simultaneously for more efficiency. The latest innovation, Angio PL.U.S offers a higher level of imaging microvascular thanks to the significantly improved sensitivity and color spatial resolution while maintaining image quality in 2D is outstanding. SuperSonic Imagine has the regulatory approvals necessary for the marketing of Aixplorer® in the main markets. SuperSonic Imagine is a company listed on Euronext since April 2014 (symbol : SSI).
For more information about SuperSonic Imagine, visit www.supersonicimagine.fr
Download the free guide
Boost your gains
